Pfizer Surprises With Q4 Profit Despite Muted COVID Products Demand, Sticks To 2024 Guidance
Pfizer's Q4 2023 financial report: adjusted EPS beats estimates at $0.10, FY2023 EPS down 72%, Q4 sales decline 41% to $14.25B. CEO's positive outlook and reaffirmed 2024 guidance.